Daratumumab is safe and induces a rapid hematological response in light-chain amyloidosis with severe cardiac impairment

Systemic light-chain (AL) amyloidosis is a plasma cell disorder characterized by extracellular deposition of monoclonal immunoglobulin light chains leading to organ dysfunction. Cardiac involvement...

[1]  M. Maurer,et al.  Daratumumab Plus CyBorD for Patients With Newly Diagnosed AL Amyloidosis: Safety Run-in Results of ANDROMEDA. , 2020, Blood.

[2]  D. Hose,et al.  Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic range albuminuria. , 2020, Blood.

[3]  S. Sarosiek,et al.  Safety, Tolerability, and Response Rates of Daratumumab in Relapsed AL Amyloidosis: Results of a Phase II Study. , 2020, Blood.

[4]  P. Hawkins,et al.  A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. , 2019, Blood.

[5]  D. Dingli,et al.  Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis , 2018, Leukemia.

[6]  J. Zonder,et al.  Daratumumab proves safe and highly effective in AL amyloidosis , 2018, British journal of haematology.

[7]  P. Morel,et al.  A Prospective Phase II of Daratumumab in Previously-Treated Systemic Light-Chain (AL) Amyloidosis , 2017 .

[8]  S. Schrier,et al.  Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. , 2017, Blood.

[9]  A. Foli,et al.  A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. , 2017, Blood.

[10]  P. Hawkins,et al.  Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens , 2014, British journal of haematology.

[11]  P. Hari,et al.  Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III) , 2014, Haematologica.

[12]  M. Dimopoulos,et al.  A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. , 2013, Blood.

[13]  M. Dimopoulos,et al.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Falk,et al.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.

[15]  T. Therneau,et al.  Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.